References
- Jain KK. Proteornics: Technologies, Markets and Companies, 10th edition. JainPharmabiotech Publications, Basel, Switzerland (2004).
- Jain KK. Personalised medicine. Carr. Opin. MoL Ther. 4,548–558 (2002).
- Jam KK. Personalized Medicine. In: Scientific & Commercial Aspects. JainPharmaBiotech Publications, Basel, Switzerland (2004).
- Jam KK. Application of laser capture microdissection to proteomics. Methods EnzymoL 356,157–167 (2002).
- Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 10, 860–868 (2004).
- Varnum SM, Covington CC, Woodbury RL et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res. Treat. 80,87–97 (2003).
- Jones MB, Krutzsch H, Shu H et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteornics2,76-84 (2002).
- Hanash SM, Bobek MP, Rickman DS et al. Integrating cancer genomics and proteomics in the post-genome era. Proteornics 2,69–75 (2002).
- Rosenblatt KP, Bryant-Greenwood P, Killian JK et al. Serum proteomics in cancer diagnosis and management. Ann. Rev. Med. 55,97–112 (2004).
- Petricoin EF III, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).
- Conrads TP, Zhou M, Petricoin EF III, Liotta L, Veenstra TD. Cancer diagnosis using proteomic patterns. Expert Rev. MoL Diagn. 3,411–420 (2003).
- Wulfkuhle JD, Aquino JA, Calvert VS et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteornics 3, 2085–2090 (2003).
- Espina V, Dettloff KA, Cowherd S, Petricoin EF III, Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin. Biol. Ther. 4,83–93 (2004).
- Ahram M, Best CJ, Flaig MJ et al. Proteomic analysis of human prostate cancer. MoL Carcinog. 33,9–15 (2002).
- David A, Mabjeesh N, Azar I et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J. Biol. Chem. 277,18084–18090 (2002).
- Meehan KL, Holland JVV, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50,54–63 (2002).
- Grubb RL, Calvert VS, Wulkuhle JD et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteornics 3,2142–2146 (2003).
- Kuerer HM, Goldknopf IL, Fritsche H et al. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 95,2276–2282 (2002).
- Turner BC, Krajewski S, Krajewska M et al. BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. Clin. OncoL 19,992–1000 (2001).
- Chakravarthy B, Pietenpol JA. Combined modality management of breast cancer: development of predictive markers through proteomics. Sernin. OncoL 30(4 Suppl. 9), 23–36 (2003).